BridgeBio Pharma (BBIO) Accumulated Expenses (2018 - 2026)

BridgeBio Pharma has disclosed Accumulated Expenses across 9 years of filings, most recently posting $39.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $39.3 million, up 17.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.3 million (up 17.61% YoY), and the FY2025 annual result was $76.7 million, up 31.5% from the prior year.
• Accumulated Expenses came in at $39.3 million for Q1 2026 at BridgeBio Pharma, down from $76.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $76.7 million in Q4 2025 to a low of $300000.0 in Q2 2024.
• The 5-year median for Accumulated Expenses is $32.4 million (2024), against an average of $31.3 million.
• Across the five-year window, Accumulated Expenses plunged 98.29% in 2024 and soared 4703.67% in 2025, its largest moves.
• BridgeBio Pharma's Accumulated Expenses stood at $17.5 million in 2022, then advanced by 1.49% to $17.8 million in 2023, then jumped by 228.41% to $58.3 million in 2024, then surged by 31.5% to $76.7 million in 2025, then plunged by 48.71% to $39.3 million in 2026.
• The last three Accumulated Expenses figures came in at $39.3 million (Q1 2026), $76.7 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.